One of the reasons Life Sciences companies are in favour right now is the resilience of many companies in the sector. Take Reva Medical (ASX: RVA) as a good example. Two years ago it looked like Reva was finished. Its focus was stents - the scaffolds that prop open blood... Show More
Steven Daghlian speaks with Reva Medical (RVA) CEO, Regina Groves about the company’s bioresorbable coronary stent and its clinical trial success To view more Executive Series interviews, visit: https://www.commsec.com.au/market-news/executive-series.html Show More